Genfit SA is a biopharmaceutical company that specializes in the discovery, development, and commercialization of therapeutic and diagnostic solutions in metabolic and liver-related diseases. The company is headquartered in Loos, France and has additional offices in the United States and Europe.
Genfit's lead product candidate is called elafibranor, which is a small molecule designed to treat nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). The drug works by targeting and regulating specific nuclear receptors that play a role in liver health and metabolism.
The company has also developed a proprietary diagnostic platform called NIS4 that uses a combination of biomarkers to detect and monitor liver diseases, including NASH. The platform is designed to help physicians make more accurate and informed treatment decisions for their patients.
Genfit has partnerships with several pharmaceutical companies to further develop and commercialize its products, including Terns Pharmaceuticals and LabCorp. The company is publicly traded on the Euronext Paris exchange under the symbol GNFT.
|
